Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?  by Carrascosa, Miguel F. et al.
Acute liver failure following atorvastatin dose escalation:
Is there a threshold dose for idiosyncratic hepatotoxicity?
To the Editor:
The bulk of hepatotoxicity (drug induced liver injury, DILI) cases
in clinical practice is idiosyncratic in nature. This assumption is
based on the apparent absence of dose dependency and the
unpredictability of the reaction, which presents after a relatively
long latency period of drug exposure in susceptible individuals.
Recent evidence suggests that the administration of high oral
daily dose of drugs that undergo extensive hepatic metabolism
does inﬂuence the risk of developing idiosyncratic DILI (IDILI)
[1,2]. We report a patient safely treated with atorvastatin at a
standard therapeutic dose for more than a year who developed
acute liver failure and rhabdomyolysis after doubling the daily
dose of the drug (Supplementary Fig. 1).
An 85-year-old woman was admitted in February 2014
because of a 4-day history of worsening drowsiness, anorexia,
jaundice, dark-yellow-coloured urine, and vomiting. Since early
January, she had complained of fatigue, decreasing ability to
walk, and sleepiness. Eighteen months prior to the episode six
intracoronary stents were placed. Past medical history included
diabetes mellitus, hypercholesterolemia, arterial hypertension,
and essential tremor. She had been receiving atorvastatin
(40 mg daily) since June 2012, along with furosemide, ramipril,
omeprazole, aspirin, metformin, and phenobarbital for more than
3 years. She had no toxic habits and denied taking over-the-coun-
ter drugs, herbal remedies, dietary supplements, or grapefruit.
Five months before admission, the atorvastatin dose was
increased to 80 mg daily due to deﬁcient lipaemic control. Liver
and renal biochemistry at the time of starting atorvastatin and
repeatedly checked thereafter up to September 2013 (prior to
atorvastatin dose escalation), had remained within the normal
range. On admission, blood pressure was 131/68 mmHg and
heart rate 78/min. Physical examination revealed jaundice, con-
fusion, and pronounced asterixis. Her body mass index was
29.5 kg/m2. Diagnostic work-up showed elevated alanine amino-
transferase (909 IU/L, n: 631), aspartate aminotransferase
(1157 IU/L, n: 631), alkaline phosphatase (415 IU/L, n: 6104),
total bilirubin (70.1 lmol/L, n: 1.7–20.5), and creatine kinase
4753 IU/L (33–185) levels, and an international normalized ratio
of 1.71. Abdominal ultrasonography revealed mild perihepatic
ascites. Serology ruled out viral hepatitis and autoimmune
disease. There was neither history nor in-hospital evidence of
syncope, hypotension or heart failure. In addition, echocardiogra-
phy displayed normal ﬁndings except for mild left ventricular
hypertrophy. Atorvastatin induced liver injury was suspected
and all drugs were stopped. After 2 days, the patient deteriorated
and developed grade IV hepatic encephalopathy (serum ammonia
level of 159 lmol/L, n: <48) (Supplementary Table 1) and hypo-
glycemia. A brain CT scan displayed no relevant abnormalities.
Under supportive treatment, however, clinical and laboratory
parameters gradually improved and she was discharged on day
12 on her habitual medications except for atorvastatin. A causal-
ity for atorvastatin, as assessed using the Roussel Uclaf Causality
Assessment Method, was probable (see Supplementary data sec-
tion). Furthermore, clinically signiﬁcant pharmacokinetic drug
interactions between atorvastatin and the rest of compounds
were judged to be highly improbable [3,4]. In April, upon coagu-
lopathy resolution, she underwent a liver biopsy, which revealed
portal hepatitis with an inﬂammatory inﬁltrate consisting of lym-
phocytes (mainly T lymphocytes) and eosinophils (Fig. 1A and B,
Supplementary Fig. 2). Of note, there was no evidence of chronic
liver disease. At a follow-up visit 7 months after discharge, she
remained well and serum transaminases, total bilirubin, and cre-
atine kinase had normalized, while alkaline phosphatase
remained slightly increased (115 IU/L).
The hepatotoxic potential of statins has been controversial
and even suggested to be a myth [5]. Recent data, however,
clearly support that these compounds can cause severe liver
damage, occasionally leading to fulminant liver failure [6,7].
A
B
Fig. 1. Liver histology. (A) Liver histology showing portal inﬂammation with
lymphocytes and eosinophils (H&E staining, 40) and (B) interface hepatitis with
associated spotty necrosis (H&E staining, 40; apoptotic body in the center).
(This ﬁgure appears in color on the web.)
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Two recent large prospective studies on DILI in the USA and in
Spain, respectively included 22 and 47 well vetted hepatotoxic-
ity cases adjudicated to statins. Atorvastatin was the most
frequently implicated drug in both cohorts [6,7]. Indeed, among
statins, atorvastatin seems to carry a higher risk of DILI with a
calculated risk of 1/3693 patients treated in a population-based
study [8].
Interestingly, the present case highlights the fact that IDILI
happened only after increasing the atorvastatin dose. This obser-
vation raises the possibility of IDILI occurring after exceeding a
threshold dose in each unique susceptible individual. Atorvastatin,
a highly lipophilic drug, is extensively metabolized by CYP3A4.
Increasing the dose of a drug with these characteristics [9] can
place a patient at a higher risk of developing IDILI. The mecha-
nisms underlying IDILI are complex, multifactorial, and poorly
understood but it is generally accepted that an interplay
between the drug’s pharmacological properties and host factors
is needed. We can speculate that enhancing the chemical drug
component might have misbalanced this cross-talk, precipitating
the event.
Existing databases of IDILI patients [6,7], which contain
detailed pharmacological information and phenotype descrip-
tion, could enable doctors to establish a risk stratiﬁcation and
determine the safe dose of drugs with presumed hepatic harmful
chemical properties.
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